Advertisement
American Association of Endocrine Surgeons| Volume 128, ISSUE 6, P973-983, December 2000

Limitations of size as a criterion in the evaluation of adrenal tumors

  • Carlton C. Barnett Jr
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Datla G. Varma
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Adel K. El-Naggar
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Alan P.B. Dackiw
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Geoffrey A. Porter
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • A.Scott Pearson
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Andrzej P. Kudelka
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Robert F. Gagel
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Douglas B. Evans
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author
  • Jeffrey E. Lee
    Affiliations
    Departments of Surgical Oncology, Radiology, Pathology, Gynecologic Medical Therapeutics, and Internal Medicine (Section of Endocrine Neoplasia and Hormonal Disorders), The University of Texas M.D. Anderson Cancer Center, Houston, Tex Houston, Texas
    Search for articles by this author

      Abstract

      Background. Size has been considered to be the single best predictor of malignancy in adrenal neoplasms that have been identified incidentally. However, small adrenal cortical cancers have been reported from multiple centers. Methods. We retrospectively evaluated the value of tumor size and other clinical parameters in the prediction of the presence of adrenal malignancy. Results. The records of 117 patients who underwent evaluation for tumors of the adrenal gland were reviewed. The median tumor size of the adrenal cortical carcinomas (n = 38 carcinomas) was 9.2 cm (range, 1.7-30 cm); 5 cancers (13.5%) were smaller than 5.0 cm. The median overall size of the benign tumors, excluding pheochromocytomas, was 4.0 cm (n = 38 carcinomas); 10 benign tumors (26%) were larger than 5.0 cm. The imaging features of 4 of 5 small adrenal cancers predicted malignancy; the remaining patients had hormonally functioning tumors. The imaging features of 7 of 10 large benign adrenal tumors predicted benign histologic features, including 5 of 5 myelolipomas. Conclusions. Although size remains a good predictor of the histologic features and clinical behavior of adrenal neoplasms, both small adrenal cortical cancers and large benign tumors occur with measurable frequency. High-quality imaging studies may be helpful in the identification of relatively small adrenal cancers and of characteristic benign lesions that may be selectively followed. (Surgery 2000;128:973-83.)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Department of Health, Education, and Welfare
        Third National Cancer Survey: incidence data.
        (NIH publication no. 41 (monograph)) : National Cancer Institute, Bethesda (MD)1975
        • Kloos RT
        • Gross MD
        • Francis IR
        • Korobkin M
        • Shapiro B
        Incidentally discovered adrenal mass.
        Endocr Rev. 1995; 16: 460-483
        • Ross NS
        • Aron DC
        Hormonal evaluation of the patient with an incidentally discovered adrenal mass.
        N Engl J Med. 1990; 323: 1401-1405
        • Angeli A
        • Osella G
        • Ali A
        • Terzolo M
        Adrenal incidentaloma: an overview of clinical and epidemiological data from the national Italian study group.
        Horm Res. 1997; 47: 279-283
        • Linos D
        • Stylopoulos N
        • Raptis SA
        Adrenaloma: a call for more aggressive management.
        World J Surg. 1996; 20: 788-792
        • Zografos GC
        • Driscoll DL
        • Karakousis CP
        • Huben RP
        Adrenal adenocarcinoma: a review of 53 cases.
        J Surg Oncol. 1994; 55: 160-164
        • Icard P
        • Louvel A
        • Chapuis Y
        Survival rates and prognostic factors in adrenocortical carcinoma.
        World J Surg. 1992; 16: 753-758
        • Pommier RF
        • Brennan MF
        An eleven year experience with adrenocortical carcinoma.
        Surgery. 1992; 62: 963-970
        • Yamakita N
        • Saitoh M
        • Mercado-Asis LB
        • Kitada M
        • Morita H
        • Yasuda K
        • et al.
        Asymptomatic adrenal tumor: 386 cases in Japan including our 7 cases.
        Endocrinol Japan. 1990; 37: 671-684
        • Fishman EK
        • Deutch BM
        • Hartman DS
        • Goldman SM
        • Zerhouni EA
        • Siegelman SS
        Primary adrenocortical carcinoma: CT evaluation with clinical correlation.
        AJR Am J Roentgenol. 1987; 148: 531-535
        • Didolkar MS
        • Bescher RA
        • Elias GE
        • Moore RH
        Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients.
        Cancer. 1981; 47: 2153-2161
        • Sullivan M
        • Boileau M
        • Hodges CV
        Adrenal cortical carcinoma.
        J Urol. 1978; 120: 660-665
        • Tang CK
        • Gray GF
        Adrenocortical neoplasms: prognosis and morphology.
        Urology. 1975; 5: 691-695
        • Bradley EL
        Primary and adjunctive therapy in carcinoma of the adrenal cortex.
        Surg Gynecol Obstet. 1975; 141: 507-516
        • Lee JE
        • Berger DH
        • El-Naggar AK
        • Hickey RC
        • Vassilopoulou-Sellin R
        • Gagel RF
        • et al.
        Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.
        Surgery. 1995; 118: 1090-1098
        • Dunnick NR
        • Korobkin M
        • Francis I
        Adrenal radiology: distinguishing benign from malignant adrenal masses.
        AJR Am J Roentgenol. 1996; 167: 861-867
        • Copeland PM
        The incidentally discovered adrenal mass.
        Ann Intern Med. 1983; 98: 940-945
        • Staren ED
        • Prinz RA
        Selection of patients with adrenal incidentalomas for operation.
        Surg Clin North Am. 1995; 75: 499-569
        • Herrera MF
        • Grant CS
        • van Heerden JA
        • Sheedy PF
        • Ilstrup DM
        Incidentally discovered adrenal tumors: an institutional perspective.
        Surgery. 1991; 110: 1014-1021
        • Graham DJ
        • McHenry CR
        The adrenal incidentaloma: guidelines for evaluation and recommendations for management.
        Surg Oncol Clin North Am. 1998; 7: 749-764
        • Terzolo M
        • Ali A
        • Giangiacomo O
        • Mazza E
        Prevalence of adrenal carcinoma among incidentally discovered adrenal masses.
        Arch Surg. 1997; 132: 914-919
        • Lau H
        • Lo CY
        • Lam KY
        Surgical implications of underesti-mating adrenal size by computed tomography.
        Br J Surg. 1999; 86: 385-387
        • Linos DA
        • Stylopoulos N
        How accurate is computed tomography in predicting the real size of adrenal tumors? A retrospective review.
        Arch Surg. 1997; 132: 740-743
      1. Dackiw APB, Lee JE, Gagel RF, Evans DB. Adrenal Cortical Carcinoma. World J Surg. (In press.)

        • Boland GW
        • Lee MJ
        Magnetic resonance imaging of the adrenal gland.
        Crit Rev Diagn Imaging. 1995; 36: 115-174